Cost effectiveness analysis of Stem Cell therapy in IschEmic Non-treatable Cardiac disease – (SCIENCE) – University of Copenhagen

Forward this page to a friend Resize Print Bookmark and Share

CHEP > Current research projects > Cost effectiveness ana...

20 May 2015

Cost effectiveness analysis of Stem Cell therapy in IschEmic Non-treatable Cardiac disease – (SCIENCE)

Cost effectiveness analysis of Stem Cell therapy in IschEmic Non-treatable Cardiac disease – (SCIENCE)
Ischemic heart disease (IHD) caused by coronary artery disease is the most common cause of death with more than 17 million deaths worldwide each year and a major cause of hospital admissions in industrialised countries. It is an increasing economic health problem due to increasing morbidity in an ageing population. Classical therapies have reduced mortality of IHD significantly, but left an increasing number of patients with chronic IHD and/or heart failure without further treatment options. IHD is normally considered to be almost exclusively a male disease. However, with the on-going social changes in life styles as smoking, adipositas and diabetes more and more women also develop coronary artery disease and heart failure.

Thus, there is an unmet need for novel, effective treatments for chronic IHD and heart failure to improve patient’s survival and quality of life and reduce health care costs. Stem cell therapy is emerging as a viable therapeutic option in this patient group as well as in several debilitating diseases for which no cure is currently available.

The aim of this study is to establish the relevant clinical documentation of the regenerative capacity of CSCC_ASC treatment in patients with heart failure and to evaluate the cost effectiveness of allogeneic CSCC_ASC therapy as standard care therapy in patients with ischemic heart failure in European Countries.

The project is funded by EU Horizon 2020.

Contact: Hans Keiding and Karsten Vrangbæk